Please wait...


Generic Name: necitumumab (NE si TOOM oo mab)
Brand Name: Portrazza
Physician reviewed Portrazza patient information - includes Portrazza description, dosage and directions.
  • Prescription Settings

Prices and coupons of Portrazza

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Portrazza is a monoclonal antibody that blocks a certain protein in the body that can affect tumor cell growth. Monoclonal antibodies are made to target and destroy only certain cells in the body. This may help to protect healthy cells from damage. Portrazza is used to treat a certain type of non-small cell lung cancer. This medicine is usually given in combination with other cancer medications. Portrazza may also be used for purposes not listed in this medication guide. Portrazza can cause your electrolytes to become unbalanced. This can lead to serious heart problems, including cardiac arrest. You will need frequent blood tests to check your electrolytes (calcium, potassium, and magnesium). Learn more

Portrazza Side Effects

Portrazza Side Effects

Note: This document contains side effect information about necitumumab. Some of the dosage forms listed on this page may not apply to the brand name Portrazza.

In Summary

Common side effects of Portrazza include: skin fissure, hypomagnesemia, acne vulgaris, acneiform eruption, dermatological reaction, maculopapular rash, pruritus, skin rash, erythema of skin, and xeroderma. See below for a comprehensive list of adverse effects.

For the Consumer

Applies to necitumumab: intravenous solution


Intravenous route (Solution)

Cardiopulmonary arrest and/or sudden death have been reported with necitumumab in combination with gemcitabine and cisplatin. Monitor serum electrolytes, including serum magnesium, potassium, and calcium. Hypomagnesemia has been reported with necitumumab plus gemcitabine and cisplatin. Monitor for hypomagnesemia, hypocalcemia, and hypokalemia prior to each necitumumab dose and for at least 8 weeks after discontinuation. Withhold treatment if grade 3 or 4 electrolyte abnormalities occur.

Along with its needed effects, necitumumab (the active ingredient contained in Portrazza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking necitumumab:

More common

  • Abdominal or stomach cramps
  • confusion
  • convulsions
  • decreased urine
  • difficulty with breathing
  • drowsiness
  • dry mouth
  • increased thirst
  • irregular heartbeat
  • loss of appetite
  • mood or mental changes
  • muscle cramps in the hands, arms, feet, legs, or face
  • muscle pain or muscle spasms (tetany) or twitching
  • nausea or vomiting
  • numbness and tingling around the mouth, fingertips, or feet
  • tremor
  • unusual tiredness or weakness

Less common

  • Anxiety
  • back pain
  • chest pain or discomfort
  • chest tightness
  • chills
  • cough
  • difficulty with speaking
  • dizziness or lightheadedness
  • double vision
  • fainting
  • fast heartbeat
  • fever
  • flushing
  • headache
  • heart stops
  • inability to move the arms, legs, or facial muscles
  • no breathing
  • no pulse or blood pressure
  • pain or discomfort in the arms, jaw, back, or neck
  • pain, redness, or swelling in the arm or leg
  • pains in the chest, groin, or legs, especially the calves of the legs
  • severe headaches of sudden onset
  • slow speech
  • sudden loss of coordination
  • sudden onset of slurred speech
  • sudden shortness of breath or troubled breathing
  • sudden vision changes
  • sweating
  • trouble breathing
  • unconscious

Some side effects of necitumumab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Blemishes on the skin
  • burning, dry, or itching eyes
  • decreased weight
  • diarrhea
  • discharge or excessive tearing
  • dry skin
  • itching skin or rash
  • loosening of the fingernails
  • pimples
  • rash with flat lesions or small raised lesions on the skin
  • redness or soreness around the fingernails
  • redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
  • swelling or inflammation of the mouth

For Healthcare Professionals

Applies to necitumumab: intravenous solution


Common (1% to 10%): Venous thromboembolic events (VTE), arterial thromboembolic events (ATE), phlebitis

Frequency not reported: Cardiopulmonary arrest


Very common (10% or more): Rash (44%), dermatitis acneiform (15%)

Common (1% to 10%): Acne, pruritus, dry skin, skin fissures


Very common (10% or more): Vomiting (29%), diarrhea (16%), stomatitis (11%)

Common (1% to 10%): Dysphagia, mouth ulceration


Frequency not reported: Infusion related reactions


Very common (10% or more): Hypomagnesemia (83%), hypocalcemia (45%), hypocalcemia (albumin corrected) (36%), hypophosphatemia (31%), hypokalemia (28%), weight loss (13%)

Nervous system

Very common (10% or more): Headache (11%)

Common (1% to 10%): Dysgeusia


Common (1% to 10%): Conjunctivitis (includes conjunctivitis, eye irritation, vision blurred, conjunctivitis bacterial, dry eye, visual acuity reduced, blepharitis, allergic blepharitis, conjunctiva hemorrhage, eye infection, eye pain, lacrimation increased, ocular hyperemia, Sjogren's syndrome, visual impairment, and eye pruritus)

Frequency not reported: Eyelash trichomegaly


Frequency not reported: Non-Squamous NSCLC -increased toxicity and increased mortality


Very common (10% or more): Hemoptysis (10%)

Common (1% to 10%): Pulmonary embolism, epistaxis, oropharyngeal pain


Common (1% to 10%): Hypersensitivity reactions


Common (1% to 10%): Paronychia


Common (1% to 10%): Muscle spasms


Common (1% to 10%): Urinary tract infection, dysuria


Common (1% to 10%): Pyrexia

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Portrazza